ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $82.75 Consensus Target Price from Analysts

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have been given a consensus rating of “Buy” by the four ratings firms that are presently covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a buy recommendation. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $82.75.

Several research analysts have recently commented on the stock. HC Wainwright raised their price objective on shares of ANI Pharmaceuticals from $87.00 to $94.00 and gave the company a “buy” rating in a research note on Wednesday, June 26th. Guggenheim restated a “buy” rating and issued a $77.00 target price on shares of ANI Pharmaceuticals in a report on Tuesday, April 23rd.

ANI Pharmaceuticals Price Performance

Shares of ANIP stock opened at $63.26 on Thursday. The company has a market capitalization of $1.33 billion, a PE ratio of 39.54 and a beta of 0.75. ANI Pharmaceuticals has a 12 month low of $48.20 and a 12 month high of $70.81. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.95 and a quick ratio of 3.12. The firm’s 50-day moving average is $62.95 and its two-hundred day moving average is $62.80.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, May 10th. The specialty pharmaceutical company reported $0.95 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.16. ANI Pharmaceuticals had a net margin of 6.87% and a return on equity of 17.15%. The firm had revenue of $137.43 million during the quarter, compared to analysts’ expectations of $125.01 million. Analysts predict that ANI Pharmaceuticals will post 3.32 earnings per share for the current year.

Insider Activity at ANI Pharmaceuticals

In other news, SVP Chad Gassert sold 20,000 shares of the firm’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $66.62, for a total value of $1,332,400.00. Following the completion of the sale, the senior vice president now owns 233,226 shares in the company, valued at approximately $15,537,516.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Nikhil Lalwani sold 16,669 shares of ANI Pharmaceuticals stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $66.10, for a total transaction of $1,101,820.90. Following the completion of the transaction, the chief executive officer now directly owns 377,505 shares in the company, valued at approximately $24,953,080.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Chad Gassert sold 20,000 shares of the business’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $66.62, for a total value of $1,332,400.00. Following the completion of the transaction, the senior vice president now directly owns 233,226 shares of the company’s stock, valued at $15,537,516.12. The disclosure for this sale can be found here. Insiders have sold 168,202 shares of company stock worth $10,719,774 in the last quarter. Company insiders own 12.70% of the company’s stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Pacer Advisors Inc. purchased a new position in shares of ANI Pharmaceuticals during the fourth quarter valued at approximately $41,000. AJOVista LLC purchased a new stake in shares of ANI Pharmaceuticals in the fourth quarter valued at $58,000. SG Americas Securities LLC acquired a new position in ANI Pharmaceuticals in the first quarter valued at $106,000. China Universal Asset Management Co. Ltd. lifted its position in ANI Pharmaceuticals by 361.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,367 shares of the specialty pharmaceutical company’s stock worth $131,000 after buying an additional 1,854 shares during the period. Finally, ADAR1 Capital Management LLC acquired a new stake in ANI Pharmaceuticals in the 4th quarter worth about $132,000. 76.05% of the stock is owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.